FDA Public Meeting on Patient-Focused Drug Development for Long COVID
The U.S. Food and Drug Administration (FDA) is hosting a virtual public meeting 25 April 2023 on Patient-Focused Drug Development for Long COVID. This meeting will provide FDA the opportunity to obtain initial patient and patient representative input on the aspects of Long COVID, including how Long COVID affects their daily life, symptoms that matter